Treatment of a Severe Form of Euglycemic Ketoacidosis in a Patient Treated with SGLT-2 Inhibitors with the Aid of Somatostatin.
SGLT-2
euglycemic ketoacidosis
somatostatin
Journal
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia
ISSN: 1724-5990
Titre abrégé: G Ital Nefrol
Pays: Italy
ID NLM: 9426434
Informations de publication
Date de publication:
31 Aug 2023
31 Aug 2023
Historique:
medline:
3
11
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
epublish
Résumé
Currently, the use of SGLT2 inhibitors is becoming more widespread, both for their role in controlling diabetes, and for their pleiotropic effects on glomerular hyperfiltration and heart failure. Along with their positive effects, these drugs can lead to various complications, the most severe being euglycemic ketoacidosis. The clinical case we have reported precisely describes this potentially serious complication which occurred in a 47-year-old patient who had been on SGLT2 inhibitor therapy for 5 years. In the resolution of this case we used, in addition to standard therapy, the continuous infusion of somatostatin, resulting in a rapid resolution of ketoacidosis and an improvement in the clinical condition.
Substances chimiques
Sodium-Glucose Transporter 2 Inhibitors
0
Somatostatin
51110-01-1
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright by Società Italiana di Nefrologia SIN, Rome,Italy.